JPRN-jRCTs051220187招募中Unknown
Amelioration of beta cell function in drug-naive type 2 diabetes with tofogliflozin, oral semaglutide or imeglimin: A multicenter randomized trial - (ABCD-TO-SEIZE trial)
Furukawa Yasushi0 个研究点目标入组 87 人开始时间: 2023年3月9日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients aged at least 18 years at the time of consent acquisition.
- •2) Patients with type 2 diabetes requiring medication.
- •3) Patients who have never been treated with medication for type 2 diabetes.
- •4) Patients with HbA1c less than 9.0%.
- •5) Patients who have the capacity to consent and have provided written informed consent.
排除标准
- •(1) Patients with type 1 diabetes.
- •(2) Patients requiring insulin therapy (e.g., insulin-dependent, insulin-independent but requiring insulin therapy to correct hyperglycemia, severe ketosis, diabetic coma or pre-coma, severe infection, pre- or postoperative, severe pancreatic disease, severe trauma).
- •(3) Patients with a history of taking alpha glucosidase inhibitors or SGLT2 inhibitors.
- •(4) Patients who are pregnant or lactating or may be pregnant or wish to become pregnant during the research period.
- •(5) Patients with inadequately treated endocrine disorders (e.g., pituitary, adrenal or thyroid disease).
- •(6) Patients with heart failure symptoms of NYHA functional class III or IV.
- •(7) Patients with diagnosed or suspected malignancy.
- •(8) Patients treated with oral or injectable corticosteroids.
- •(9) Patients with eGFR <45 mL/min/1.72 m^2.
- •(10) Patients with severe liver disease (AST or ALT > 100 IU/L).
- •(11) Patients with poorly controlled dysuria due to neurogenic bladder, benign prostatic hyperplasia, etc.
- •(12) Patients with symptomatic urinary tract infection or genital infection.
- •(13) Patients with a history of cerebral infarction.
- •(14) Patients with a history of renal disease, such as nephrectomy, renal transplantation, etc.
- •(15) Patients who underwent gastrectomy.
- •(16) Patients who cannot avoid eating, drinking, or taking other medications for at least 30 minutes after waking up.
- •(17) Patients currently participating in other interventional trials (including clinical trials).
- •(18) Patients judged as ineligible for participation in this study by the Principal Investigator, Site Principal Investigator or Sub-Investigator.
研究者
相似试验
已完成
不适用
Effect of therapy on residual beta cell function in type-1 diabetes mellitusNutritional, Metabolic, EndocrineType 1 diabetes mellitusDiabetes mellitusISRCTN70703138Justus Liebig University (Germany)
尚未招募
不适用
A retrospective study on beta cell function in type 2 diabetic patients using GLP-1 receptor agonistType 2 diabetes mellitusJPRN-UMIN000031697Showa University of medicine, the department of internal medicine, the division of diabetology, metabolism and endocrinology60
已完成
不适用
Study on association between beta cell function and glycemic variability in the non-diabetic subjects with normal glucose tolerance and impaired glucose tolerancediabetesJPRN-UMIN000020002Kobe University Graduate School of Medicine100
进行中（未招募）
4 期
Investigating cardiac energy levels in people with lean-type type 2 diabetesType 2 diabetes mellitusNutritional, Metabolic, EndocrineISRCTN85605342niversity of Leeds56
已完成
早期 1 期
Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1DType 1 DiabetesNCT05847413Benaroya Research Institute10